PTC Therapeutics, Inc. (PTCT) today announced that the FDA has accepted the New Drug Application for Vatiquinone, a proposed treatment for Friedreich's ataxia, and granted Priority Review. The U.S. regulatory agency has set the target action date for August 19, 2025.Friedreich's ataxia, a rare, progressive, and debilitating genetic disorder, causes muscle weakness, coordination problems, and heart...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.